Researcher

    Thomas Pincez , M.D. , Ph.D. , FRCPC

    thomas.pincez@umontreal.ca
    Thomas Pincez
    Research Axis
    Immune Diseases and Cancer Axis
    Research Theme
    Severe hematologic diseases

    Title

    • Assistant professor, département de pédiatrie, Faculté de médecine, Université de Montréal (2024)
    • Researcher, Centre de recherche Azrieli du CHU Sainte-Justine (2024)

    Education

    • PhD in molecular biology (option complex disease in human), University of Montréal, 2020-2023
    • Pediatrics and Pediatric Hematology/Oncology certifications, Royal College of Physicians and Surgeons of Canada, 2023
    • Specialist diploma (fellow) in Pediatric Hematology-Oncology, CHU Sainte-Justine, University of Montréal, 2018-2021
    • Specialist diploma in Pediatrics, Paris Descartes University, 2012-2017
    • Doctor of Medicine (MD), Paris Descartes University, 2006-2017
    • Post Graduate Program in Pediatric Nutrition, Boston University School of Medicine, 2017
    • Master (MSc) of Immunology, Paris Est-Créteil University (internship at Maisonneuve-Rosemont hospital research center, Montréal), 2015-2016 
    • Inter-University diploma Daily practice in child pain, Paris Sud University/UPMC, 2015
    • Inter-University diploma Pediatric Immuno-Hematology, Lyon 1 Claude-Bernard University, 2014  

    Research Interests

    Dr. Pincez's research laboratory aims to use clinical, genetic, and genomic tools to improve the understanding, stratification, and prognosis of autoimmune cytopenias and red blood cell disorders. The objective is to bring the benefits of these approaches to patients in order to adapt and personalize care. To that end, they use different DNA sequencing approaches to study the effect of rare and frequent constitutional variants as well as somatic variants (clonal hematopoiesis). They also use RNA sequencing and proteomics approaches, coupled with clinical data in an integrative approach.

    Research Topics

    • Autoimmune cytopenias
    • Red blood cell disorders
    • Constitutional and acquired genetic contribution to hematological disorders
    • Biomarkers of evolution, prognosis, and response to treatment
    • Clonal hematopoiesis
    • Statistical genetics
    • Genomics

    Career Summary

    Dr. Pincez completed his clinical training in pediatrics and then in pediatric hematology-oncology at Paris Descartes University and at CHU Sainte-Justine. His clinical practice and research interests focus on classical (non-malignant) hematology, particularly in autoimmune cytopenias and red blood cell disorders. He has carried out numerous clinical research studies in order to identify prognostic subgroups of the evolution and response to treatments in these two groups of pathologies. He also completed a master's degree in immunology at Paris Est-Créteil University and a PhD in molecular biology supervised by Pr Guillaume Lettre at the Montreal Heart Institute. During his PhD, Dr. Pincez used different genetic tools (study of clonal hematopoiesis, genome-wide association studies, polygenic scores, Mendelian randomization and CRISPR/Cas9 genetic screening) in order to identify the effect of genetic variations on the expression of sickle cell disease, and conversely the effect sickle cell disease on the expression of genetic determinants. 

    Research laboratory

    Precision globulomics

    Awards and Distinctions

    • Prix relève étoile Jacques-Genest, Fonds de recherche du Québec en santé, 2022 
    • Prix Martin Gyger, Quebec Association of Hematologists-Oncologists, 2019
    • Paris Medicine Faculty Laureate (Silver Medal), 2017 
    • French Pediatric Society (SFP) Award, 2015 
    • Travel award, club du globule rouge et du fer, 2014 et 2015
    • Best dissertation Award from French Paediatric Immuno-Hematology Society (SHIP), 2014

    Presentations

    • Anémies en pédiatrie. Congrès de l’association des infirmières praticiennes spécialisées du Québec, Trois-Rivières, Québec, avril 2024 (conférencier invité).
    • Does sickle cell disease influence genetic variations inherited at birth and those acquired throughout life? Studies of hematological traits and clonal hematopoiesis. Conférence nationale sur l’anémie falciforme, associations d’anémie falciforme du Canada et du Québec, Montréal, Canada, septembre 2023 (conférencier invité).
    • Impact de l'âge au diagnostic et du sexe sur l’évolution de 886 patients avec purpura thrombopénique immunologique chronique. Congrès de la Société Française de Pédiatrie, Marseille, France, juin 2023.
    • Résultats à long-terme et facteurs prédictifs après splénectomie pour cytopénie auto-immune de l’enfant : données de la cohorte OBS’CEREVANCE. Journée nationale du Centre de Référence des Cytopénies Auto-immunes de l’Enfant, virtuel, France, juin 2021 (conférencier invité).
    • Brentuximab Vedotin for lymphoproliferative diseases in primary immunodeficiencies. Biennial Meeting of the European Society for Immunodeficiencies, Lisbonne, Portugal, octobre 2018.   

    Publications

    • Pincez T, Fernandes H, Fahd M, Pasquet M, Abou Chahla W, Granel J, Ducassou S, Thomas C, Garnier N, Barlogis V, Jeziorski E, Bayart S, Chastagner P, Cheikh N, Guitton C, Paillard C, Lejeune J, Millot F, Li-Thiao Te V, Mallebranche C, Pellier I, Neven B, Armari-Alla C, Carausu L, Piguet C, Benadiba J, Pluchart C, Stephan JL, Deparis M, Briandet C, Doré E, Marie-Cardine A, Leverger G, Héritier S, Aladjidi N, Leblanc T. Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome. American Journal of Hematology 2024
    • Pincez T, Lettre G. Re-assessing the effect of fetal hemoglobin on stroke in the Cooperative Study of Sickle Cell Disease. American Journal of Hematology 2023
    • Pincez T, Fernandes H, Pasquet M, Abou Chahla W, Granel J, Héritier S, Fahd M, Ducassou S, Thomas C, Garnier N, Barlogis V, Jeziorski E, Bayart S, Chastagner P, Cheikh N, Guitton C, Paillard C, Lejeune J, Millot F, Li-Thiao Te V, Mallebranche C, Pellier I, Neven B, Armari-Alla C, Carausu L, Piguet C, Benadiba J, Pluchart C, Stephan JL, Deparis M, Briandet C, Doré E, Marie-Cardine A, Leblanc T, Leverger G, Aladjidi N. Impact of age at diagnosis, sex, and immunopathological manifestations in 886 patients with pediatric chronic immune thrombocytopenia. American Journal of Hematology 2023
    • Pincez T, Lo KS, D’Orengiani ALPH d’Alexandry, Garrett ME, Brugnara C, Ashley-Koch AE, Telen MJ, Galacteros F, Joly P, Bartolucci P, Lettre G. Variation and impact of polygenic hematological traits in monogenic sickle cell disease. Haematologica 2023
    • Pincez T, Ashley-Koch AE, Lettre G, Telen MJ. Genetic Modifiers of Sickle Cell Disease. Hematology/Oncology Clinics of North America 2022
    • Pincez T, Aladjidi N, Heritier S, Garnier N, Fahd M, Abou Chahla W, Fernandes H, Dichamp C, Ducassou S, Pasquet M, Bayart S, Moshous D, Cheikh N, Paillard C, Plantaz D, Jeziorski E, Thomas C, Guitton C, Deparis M, Cardine A, Stephan JLL, Pellier I, Doré E, Benadiba J, Pluchart C, Briandet C, Barlogis V, Leverger G, Leblanc TM. Determinants of long-term outcomes of splenectomy in pediatric autoimmune cytopenias. Blood 2022
    • Pincez T, Fernandes H, Leblanc T, Michel G, Barlogis V, Bertrand Y, Neven B, Chahla WA, Pasquet M, Guitton C, Marie-Cardine A, Pellier I, Armari-Alla C, Benadiba J, Blouin P, Jeziorski E, Millot F, Paillard C, Thomas C, Cheikh N, Bayart S, Fouyssac F, Piguet C, Deparis M, Briandet C, Dore E, Picard C, Rieux-Laucat F, Landman-Parker J, Leverger G, Aladjidi N. Long term follow-up of pediatric-onset Evans syndrome: broad immunopathological manifestations and high treatment burden. Haematologica 2022
    • Pincez T, Lee SSK, Ilboudo Y, Preuss M, Pham Hung d’Alexandry d’Orengiani AL, Bartolucci P, Galactéros F, Joly P, Bauer DE, Loos RJF, Lindsley RC, Lettre G. Clonal hematopoiesis in sickle cell disease. Blood 2021
    • Pincez T, Bruneau J, Berteloot L, Piekarski E, Thomas C, Marçais A, Trinquand A, Castelle M, Garcelon N, Plantaz D, Cheminant M, Moshous D, Molina TJ, Hermine O, Macintyre E, Fischer A, Blanche S, Suarez F, Neven B. Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies. Haematologica 2020
    • Pincez T, Guitton C, Gauthier F, de Lambert G, Picard V, Fénéant-Thibault M, Turhan A, Mohandas N, Tchernia G, Garçon L. Long-term follow-up of subtotal splenectomy for hereditary spherocytosis: a single-center study. Blood 2016
 

Grow Beyond our wildest dreams

With the support of donors like you, at the heart of the Grow Beyond campaign, we are leading healthcare teams towards the opportunities offered by science and new technologies, so that every child, no matter where in Quebec, has access to the unique expertise and know-how of CHU Sainte-Justine. Together, let's join forces for their future.

Grow Beyond with us.

Contact Us

514 345-4931

Légal

© 2006-2014 CHU Sainte-Justine.
All rights reserved.
Terms of Use, Confidentiality, Security

Avertissement

Les informations contenues dans le site « CHU Sainte-Justine » ne doivent pas être utilisées comme un substitut aux conseils d’un médecin dûment qualifié et autorisé ou d’un autre professionnel de la santé. Les informations fournies ici le sont à des fins exclusivement éducatives et informatives.

Consultez votre médecin si vous croyez être malade ou composez le 911 pour toute urgence médicale.

CHU Sainte-Justine